Published in PLoS Negl Trop Dis on September 27, 2011
Genotypes and mouse virulence of Toxoplasma gondii isolates from animals and humans in China. PLoS One (2013) 1.22
Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol (2012) 0.98
Neglected parasitic infections in the United States: toxoplasmosis. Am J Trop Med Hyg (2014) 0.96
Congenital Toxoplasmosis. J Pediatric Infect Dis Soc (2014) 0.92
Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis (2014) 0.91
Multiplexed Anti-Toxoplasma IgG, IgM, and IgA Assay on Plasmonic Gold Chips: towards Making Mass Screening Possible with Dye Test Precision. J Clin Microbiol (2016) 0.82
Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep (2016) 0.80
Understanding Toxoplasmosis in the United States Through "Large Data" Analyses. Clin Infect Dis (2016) 0.78
Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Negl Trop Dis (2017) 0.77
Reply to Wallon and Peyron. Clin Infect Dis (2015) 0.75
Identification, production and assessment of two Toxoplasma gondii recombinant proteins for use in a Toxoplasma IgG avidity assay. Pathog Glob Health (2016) 0.75
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis (2015) 0.75
The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study. BMC Pregnancy Childbirth (2016) 0.75
Prematurity and Low Birth Weight did not Correlate with Anti-Toxoplasma gondii Maternal Serum Profiles--a Brazilian Report. PLoS One (2015) 0.75
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis (2017) 0.75
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83
Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol (2006) 5.99
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med (1994) 4.32
Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol (2001) 4.12
Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J Clin Microbiol (1997) 3.34
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med (1988) 3.15
Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg (2007) 3.09
The economic value of life: linking theory to practice. Am J Public Health (1982) 3.03
Results of 20-year follow-up of congenital toxoplasmosis. Lancet (1986) 3.00
Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr (1989) 2.98
Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med (1994) 2.94
Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis (2001) 2.86
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis (2001) 2.74
Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis (2008) 2.73
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol (2005) 2.66
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis (2006) 2.63
Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis (1994) 2.58
Genetic diversity, clonality and sexuality in Toxoplasma gondii. Int J Parasitol (2004) 2.54
Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet (2007) 2.37
Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci U S A (2006) 2.17
Oocyst-transmitted toxoplasmosis associated with ingestion of contaminated water. N Engl J Med (1982) 2.07
Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect Dis (2006) 2.00
Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol (1999) 1.92
Genetic analyses of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int J Parasitol (2011) 1.88
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol (1997) 1.85
Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med (1974) 1.69
Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics (1977) 1.66
Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Med (1974) 1.64
Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis J (2011) 1.57
Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis. Am J Obstet Gynecol (2009) 1.54
Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis (2008) 1.49
The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol (2010) 1.48
Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz (2009) 1.45
Congenital toxoplasmosis in France in 2007: first results from a national surveillance system. Euro Surveill (2010) 1.42
Prenatal screening for toxoplasmosis. Obstet Gynecol (1997) 1.41
[Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy]. Ann Pediatr (Paris) (1984) 1.36
Congenital toxoplasmosis: a prospective study of 4,048 obstetric patients. Am J Obstet Gynecol (1971) 1.35
Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics (2004) 1.34
Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol (1996) 1.31
Genetic characterisation of Toxoplasma gondii in wildlife from North America revealed widespread and high prevalence of the fourth clonal type. Int J Parasitol (2011) 1.30
Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol (2004) 1.28
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J Antimicrob Chemother (1988) 1.23
Detection of Toxoplasma gondii oocysts in drinking water. Appl Environ Microbiol (1998) 1.23
Evaluation of the possibilities for preventing congenital toxoplasmosis. Am J Perinatol (1994) 1.22
Toxoplasma gondii infection in the United States, 1999-2000. Emerg Infect Dis (2003) 1.22
Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother (1992) 1.19
Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth. J Med Screen (2007) 1.18
Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Dev Med Child Neurol (1962) 1.16
Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med (2010) 1.13
Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology (2009) 1.11
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Congenital toxoplasmosis. The Toxoplasmosis Study Group. Semin Pediatr Neurol (1994) 1.10
Genetic analysis of the diversity in Toxoplasma gondii. Ann Ist Super Sanita (2004) 1.09
High prevalence and genotypes of Toxoplasma gondii isolated from goats, from a retail meat store, destined for human consumption in the USA. Int J Parasitol (2011) 1.09
Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology (2007) 1.09
Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J (2008) 1.09
Changing climate-changing pathogens: Toxoplasma gondii in North-Western Europe. Parasitol Res (2009) 1.07
Identification of an atypical strain of toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, Brazil. J Infect Dis (2010) 1.07
Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol (2005) 1.04
New Toxoplasma gondii genotypes isolated from free-range chickens from the Fernando de Noronha, Brazil: unexpected findings. J Parasitol (2010) 1.02
Epidemiology of congenital toxoplasmosis identified by population-based newborn screening in Massachusetts. Pediatr Infect Dis J (2001) 1.02
Evaluation of Toxoplasma gondii immunoglobulin G (IgG) and IgM assays incorporating the newVidia analyzer system. Clin Vaccine Immunol (2008) 1.01
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol (2003) 0.99
A simple model relevant to toxoplasmosis applied to epidemiologic results in France. Am J Epidemiol (1986) 0.99
Diagnosis of congenital toxoplasmosis in the neonatal period: A multicenter evaluation. J Pediatr (1999) 0.97
Direct genotyping of animal and human isolates of Toxoplasma gondii from Colombia (South America). Acta Trop (2005) 0.97
Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol (2010) 0.97
Maternal serologic screening for toxoplasmosis. J Midwifery Womens Health (2003) 0.95
Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol (2006) 0.95
[Infectious fetal diseases. Prevention, prenatal diagnosis, practical measures]. Presse Med (1991) 0.94
Lifetime costs of cerebral palsy. Dev Med Child Neurol (2009) 0.94
Treatment for congenital toxoplasmosis: finding out what works. Mem Inst Oswaldo Cruz (2009) 0.93
Screening by ophthalmoscopy for Toxoplasma retinochoroiditis in Colombia. Am J Ophthalmol (2006) 0.92
[Ocular prognosis in congenital toxoplasmosis: the role of treatment. Preliminary communication]. Ann Pediatr (Paris) (1984) 0.92
Factors affecting the adherence to an antenatal screening programme: an experience with toxoplasmosis screening in France. Euro Surveill (2009) 0.86
Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. Centers for Disease Control and Prevention. MMWR Recomm Rep (1995) 0.85
Commentary: Efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol (2001) 0.84
Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.82
Isolation, tissue distribution, and molecular characterization of Toxoplasma gondii from free-range chickens from Guatemala. J Parasitol (2005) 0.80
Is routine antenatal toxoplasmosis screening justified in the United States? Statistical considerations in the application of medical screening tests. Clin Obstet Gynecol (1999) 0.80
Positive benefit of postnatal treatment in congenital toxoplasmosis. Arch Dis Child (2007) 0.78
Congenital toxoplasmosis: long-term follow-up. Padiatr Padol (1982) 0.77
What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to say. Am J Obstet Gynecol (2010) 0.76
The value of a statistical life in Sweden: estimates from two studies using the "Certainty Approach" calibration. Accid Anal Prev (2009) 0.76
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol (2005) 2.66
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis (2012) 2.13
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol (2002) 1.58
NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun (2010) 1.46
Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz (2009) 1.45
Evolutionary origins of the eukaryotic shikimate pathway: gene fusions, horizontal gene transfer, and endosymbiotic replacements. Eukaryot Cell (2006) 1.44
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation (2008) 1.41
P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol (2010) 1.33
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One (2008) 1.32
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J (2011) 1.25
Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm (2011) 1.13
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics (2006) 1.10
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase. Acta Crystallogr D Biol Crystallogr (2003) 1.09
Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology (2007) 1.09
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother (2012) 1.07
Genetic analysis of influences on survival following Toxoplasma gondii infection. Int J Parasitol (2002) 1.04
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology (2011) 1.02
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry (2007) 1.00
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr (2007) 0.98
Cataracts in congenital toxoplasmosis. J AAPOS (2007) 0.98
In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol (2002) 0.97
T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One (2010) 0.96
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A (2012) 0.95
Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.95
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol (2011) 0.94
The unusual mitochondrial compartment of Cryptosporidium parvum. Trends Parasitol (2005) 0.93
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2005) 0.92
Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem (2012) 0.87
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorg Med Chem Lett (2013) 0.84
Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol (2010) 0.84
Subcellular localization and dynamics of a digalactolipid-like epitope in Toxoplasma gondii. J Lipid Res (2008) 0.84
Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.83
Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun (2012) 0.83
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2013) 0.82
Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania. J Med Chem (2012) 0.80
Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med (Porto Alegre) (2010) 0.79
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem (2013) 0.77
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry (2013) 0.77
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett (2013) 0.76
Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des (2011) 0.76
Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. J Neuroparasitology (2012) 0.75